INM trade ideas
INM | This is a Runner | LONGInMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Looks like a great buying opportunity Looks like a great buying opportunity, the stock looks highly oversold, with a short term spike in volatility, this could be a good candidates for a mind to long term bull run and considering the new report on the benefits of cannabinoids.
Huge Gap on InMed. INMInMed Pharmaceuticals produced an absolutely monster gap that now needs to be worked backwards in these very bearish circumstances. Fibs give some initial goals. Negative momentum loop done. The pull out will on a divergence or completion of Fibgoals, whichever occurs first.
InMed needs medicine. INMGoals 0.56, 0.49. Invalidation at 0.89.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
INM 1W Swing editiontest
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research and development of novel. It also involves in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
INM $7.5 target short termFirst has to maintain the .236 fib at $4.71 for me to consider an entry, getting to $7.5+ shouldn't be a problem after that.
big breakout if resistance breaks. be patient hererecently rejected at resistance, but if it breaks we know what will happen... a test of 7 and 50 percent run that day! just like pola did with it broke top trendline resistance friday! we just missed that one :( next time! good luck longs ! have a great marthin luther king jr day tomorrow <3
